Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...